摘要
为了探讨儿童急性淋巴细胞白血病(ALL)NF-κB P65蛋白的表达及意义,应用SP免疫组织化学法检测32例ALL患儿和40例非血液病的对照儿童NF-κBP65蛋白的表达。结果表明:32例ALL患儿的NF-κB P65蛋白的阳性表达率为87.50%(28/32),表达定位于ALL细胞的胞核及胞浆中,阳性表达率明显高于对照组12.50%(5/40),两者比较有显著性差异(χ2=40.28,p<0.01)。在28例ALL患儿组阳性表达者中,弱阳性表达(+)占10.71%(3/28),阳性表达(++)占42.86%(12/28),强阳性表达(+++)占46.43%(13/28)。正常对照组均为弱阳性表达(5/5),两者表达程度经Ridit分析差异有显著意义(p<0.01)。ALL病程间(初发或复发)、免疫表型间(T系ALL与B系ALL)、各细胞形态学间的表达程度差异均无显著意义(p>0.05,四格表精确概率法)。结论:NF-κB P65蛋白表达于儿童ALL细胞中,抑制NF-κB信号传导途径可能在儿童ALL治疗中有重大价值,这为临床寻求以NF-κB为靶点的治疗手段提供了科学依据。
To investigate the expression of nuclear transcription factor κB （NF-κB） in childhood acute lymphoblastic leukemia （ALL） and its significance, the biotin-streptavidin method and microscopy were used to detect NF-κB P65 protein in cells from 32 childhood ALL patients and 40 children without hematologic malignancies as control. The results showed that the positive expression rate of NF-κB P65 protein in cells from 32 childhood ALL patients was 87.50%, obviously higher than that in control group （12.50%） （X^2 =40.56, p 〈 0.01 ）. In 28 childhood ALL patients with positive expression, the ratio of weakly positive（ ＋ ） cases to all positive cases was 10.71% （3/28） ; the ratio of generally positive（ ＋＋ ） case was 42.86% （ 12/28 ）, and the ratio of strongly positive（ ＋＋＋ ） cases was 46.43% （ 13/28 ）. While in the control group the of NF-KB P65 protein showed low expression with 100% （5/5）. There was significant difference in the level of NF-κB P65 protein between ALL patients and control group. While the level of NF-κB P65 protein had no significent difference in morphology, immunophenotype （T-lineage ALL and B-lineage ALL） and the courses in the de novo and the relaspsed cases. It is concluded that NF-κB P65 protein expresses in cells of childhood ALL, the inhibition of NF-κB transduction pathway may have significant value in childhood ALL treatment. This study provides experimental basis concerning clinical treatment for ALL, when NF-κB is taken as a target.
出处
《中国实验血液学杂志》
CAS
CSCD
2007年第4期767-771,共5页
Journal of Experimental Hematology
